Published in N Am J Med Sci on November 01, 2015
A successful treatment of hypercalcemia with zoledronic acid in a 15-year-old boy with acute lymphoblastic leukemia. Ann Pediatr Endocrinol Metab (2016) 0.75
Hypercalcaemia and hypocalcaemia: finding the balance. Support Care Cancer (2017) 0.75
Treatment of aneurysmal bone cysts by percutaneous CT-guided injection of calcitonin and steroid. Skeletal Radiol (2016) 0.75
Usefulness of nuclear whole-body bone scanning for diagnosis of leprosy. Proc (Bayl Univ Med Cent) (2017) 0.75
Osteoclast differentiation and activation. Nature (2003) 18.59
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Clinical practice. Hypercalcemia associated with cancer. N Engl J Med (2005) 3.88
Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA (2004) 3.35
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol (2011) 3.07
Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. J Natl Cancer Inst (2013) 2.80
Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol (2001) 2.72
Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med (1990) 2.43
Electrocardiographic manifestations: electrolyte abnormalities. J Emerg Med (2004) 2.29
Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med (2008) 2.23
Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab (2014) 2.17
Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci (2007) 2.15
Use of denosumab in parathyroid carcinoma with refractory hypercalcemia. QJM (2014) 1.98
Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer (1993) 1.91
Rehydration in the treatment of severe hypercalcaemia. Q J Med (1981) 1.87
Hypercalcemia-induced ST-segment elevation mimicking acute myocardial infarction. J Electrocardiol (2006) 1.84
Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract (2012) 1.84
Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int (2011) 1.59
TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res (2010) 1.57
Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab (1998) 1.56
Differential diagnosis of hypercalcemia. J Bone Miner Res (1991) 1.56
Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab. Eur J Endocrinol (2014) 1.54
Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J (2006) 1.53
Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene. J Clin Endocrinol Metab (2005) 1.48
Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet (1993) 1.45
Biology of breast cancer bone metastasis. Cancer Biol Ther (2007) 1.45
Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Intern Med (1994) 1.43
Gallium inhibits bone resorption by a direct effect on osteoclasts. Bone Miner (1990) 1.42
Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab (2007) 1.39
Calcitonin: physiology and pathophysiology. N Engl J Med (1981) 1.38
Investigation of hypercalcemia. Clin Biochem (2012) 1.23
Incidence of hypercalcemia and malignant neoplasm. Arch Surg (1980) 1.15
Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Br J Dermatol (2007) 1.14
Parathyroid hormone-related protein: an update. J Clin Endocrinol Metab (2012) 1.13
The syndrome of distal (type 1) renal tubular acidosis. Clinical and laboratory findings in 58 cases. Medicine (Baltimore) (1988) 1.12
Mechanisms of intestinal calcium absorption. J Cell Biochem (2003) 1.12
The skeleton: a multi-functional complex organ: the role of key signalling pathways in osteoclast differentiation and in bone resorption. J Endocrinol (2011) 1.11
Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin. Ann Intern Med (1988) 1.07
Pathogenesis of myeloma bone disease. J Cell Biochem (2010) 1.06
Ventricular fibrillation in hypercalcaemic crisis due to primary hyperparathyroidism. Neth J Med (2004) 1.05
ST segment elevation mimicking acute myocardial infarction in hypercalcaemia. Heart (2005) 1.02
Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol (1996) 1.01
Relationship of free and total calcium in hypercalcemic conditions. J Clin Endocrinol Metab (1979) 0.99
Understanding hypercalcemia. Its metabolic basis, signs, and symptoms. Postgrad Med (2004) 0.96
Salmon calcitonin in the acute management of hypercalcemia. Calcif Tissue Int (1990) 0.96
Malignancy and concomitant primary hyperparathyroidism. J Surg Oncol (1988) 0.94
Survival in hypercalcaemic patients with cancer and co-existing primary hyperparathyroidism. Postgrad Med J (1995) 0.94
Hypercalcemia due to vitamin D intoxication with clinical features mimicking acute myocardial infarction. Intern Med (2003) 0.93
Primary hyperparathyroidism and the gastrointestinal tract. South Med J (1981) 0.92
Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years? J Transl Med (2013) 0.92
Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J Clin Invest (1984) 0.92
Denosumab for tumor-induced hypercalcemia complicated by renal failure. Ann Intern Med (2012) 0.90
Hypercalcaemia due to calcium binding by a polymeric IgA kappa-paraprotein. Ann Clin Biochem (1991) 0.88
Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD). Br J Cancer (1995) 0.88
Vitamin D metabolite-mediated hypercalcemia. Endocrinol Metab Clin North Am (1989) 0.87
Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. J Clin Endocrinol Metab (1994) 0.87
Concurrence of primary hyperparathyroidism and metastatic breast carcinoma affected a parathyroid gland. J Clin Endocrinol Metab (2013) 0.86
Small cell carcinoma of the ovary with hypercalcemia causes severe pancreatitis and altered mental status. Gynecol Oncol (2004) 0.85
Primary hyperparathyroidism. Endocr Pract (2012) 0.84
Correction of hypercalcemia and hypophosphatemia by hemodialysis using a conventional, calcium-containing dialysis solution enriched with phosphorus. Am J Kidney Dis (1997) 0.84
Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy. BMJ Case Rep (2014) 0.83
A case of multiple myeloma coexisting with primary hyperparathyroidism and review of the literature. Case Rep Oncol Med (2013) 0.82
Non-malignant causes of hypercalcemia in cancer patients: a frequent and neglected occurrence. Support Care Cancer (2012) 0.81
Parathyroid nuclear scan. A focused review on the technical and biological factors affecting its outcome. Clin Cases Miner Bone Metab (2014) 0.81
Calcium-free hemodialysis for the management of hypercalcemia. Nephron (1996) 0.81
Parathyroid hormone expression in a patient with metastatic nasopharyngeal rhabdomyosarcoma and hypercalcemia. Endocrine (2005) 0.81
Gallium nitrate inhibits accelerated bone turnover in patients with bone metastases. J Clin Oncol (1987) 0.80
Reversible renal failure caused by hypercalcemia. A retrospective study. Acta Med Scand (1978) 0.80
The risk of cancer in primary care patients with hypercalcaemia: a cohort study using electronic records. Br J Cancer (2014) 0.80
Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer (2003) 0.79
The effects of calcitonin in hypercalcemia in patients with malignancy. Cancer (1974) 0.79
Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient. Nat Clin Pract Nephrol (2006) 0.79
Posterior reversible encephalopathy syndrome due to hypercalcemia associated with parathyroid hormone-related peptide: a case report and review of the literature. Intern Med (2013) 0.78
Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer (1994) 0.78
Hypercalcemia of malignancy with simultaneous elevation in serum parathyroid hormone--related peptide and 1,25-dihydroxyvitamin D in a patient with metastatic renal cell carcinoma. Endocr Pract (2009) 0.78
Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction. Clin Lymphoma Myeloma Leuk (2014) 0.78
Nasal human calcitonin for tumor-induced hypercalcemia. Calcif Tissue Int (1992) 0.76
Posterior reversible encephalopathy syndrome due to malignant hypercalcemia: physiopathological considerations. J Clin Endocrinol Metab (2014) 0.76
Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure. Scand J Urol Nephrol (1993) 0.76